785 related articles for article (PubMed ID: 24918198)
1. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
2. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
3. Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).
Galatsis P
Expert Opin Ther Pat; 2017 Jun; 27(6):667-676. PubMed ID: 28117607
[TBL] [Abstract][Full Text] [Related]
4. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
6. Leucine-rich repeat kinase 2 mutants I2020T and G2019S exhibit altered kinase inhibitor sensitivity.
Reichling LJ; Riddle SM
Biochem Biophys Res Commun; 2009 Jun; 384(2):255-8. PubMed ID: 19397894
[TBL] [Abstract][Full Text] [Related]
7. Identification of chemicals to inhibit the kinase activity of leucine-rich repeat kinase 2 (LRRK2), a Parkinson's disease-associated protein.
Yun H; Heo HY; Kim HH; DooKim N; Seol W
Bioorg Med Chem Lett; 2011 May; 21(10):2953-7. PubMed ID: 21474311
[TBL] [Abstract][Full Text] [Related]
8. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?
Taymans JM
Expert Opin Ther Pat; 2014 Jul; 24(7):727-30. PubMed ID: 24875782
[TBL] [Abstract][Full Text] [Related]
9. Chemical Biology of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors.
Estrada AA; Sweeney ZK
J Med Chem; 2015 Sep; 58(17):6733-46. PubMed ID: 25915084
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
Seol W
BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
[TBL] [Abstract][Full Text] [Related]
11. Targeting leucine-rich repeat kinase 2 in Parkinson's disease.
Chan SL; Angeles DC; Tan EK
Expert Opin Ther Targets; 2013 Dec; 17(12):1471-82. PubMed ID: 24206363
[TBL] [Abstract][Full Text] [Related]
12. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
13. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
[TBL] [Abstract][Full Text] [Related]
14. A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry.
Leveridge M; Collier L; Edge C; Hardwicke P; Leavens B; Ratcliffe S; Rees M; Stasi LP; Nadin A; Reith AD
J Biomol Screen; 2016 Feb; 21(2):145-55. PubMed ID: 26403521
[TBL] [Abstract][Full Text] [Related]
15. Targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of Parkinson's disease.
Domingos S; Duarte T; Saraiva L; Guedes RC; Moreira R
Future Med Chem; 2019 Aug; 11(15):1953-1977. PubMed ID: 31517532
[TBL] [Abstract][Full Text] [Related]
16. MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
Fell MJ; Mirescu C; Basu K; Cheewatrakoolpong B; DeMong DE; Ellis JM; Hyde LA; Lin Y; Markgraf CG; Mei H; Miller M; Poulet FM; Scott JD; Smith MD; Yin Z; Zhou X; Parker EM; Kennedy ME; Morrow JA
J Pharmacol Exp Ther; 2015 Dec; 355(3):397-409. PubMed ID: 26407721
[TBL] [Abstract][Full Text] [Related]
17. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E; Baekelandt V; Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
[TBL] [Abstract][Full Text] [Related]
20. LRRK2 in Parkinson's disease: protein domains and functional insights.
Mata IF; Wedemeyer WJ; Farrer MJ; Taylor JP; Gallo KA
Trends Neurosci; 2006 May; 29(5):286-93. PubMed ID: 16616379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]